Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06553027 · ClinicalTrials.gov registry record · Phase 3
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
A Phase 3 study of Parkinson Disease, sponsored by Cerevance.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
- 20
- Study locations
NCT06553027: Recruiting Phase 3 study of Parkinson Disease, sponsored by Cerevance.
NCT06553027 is a Phase 3 study of Parkinson Disease that is actively recruiting participants, run by Cerevance. The registered enrollment target is 330 participants, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06553027, a Phase 3 study of Parkinson Disease, is actively recruiting participants, sponsored by Cerevance.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.
Primary Outcome
The assessment of the average daily OFF time, normalized to waking hours will be based on diaries completed at home for three consecutive days during the 7-day period before a scheduled in-person visit.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CVN424 75 mg
- DRUG CVN424 150 mg
Study Locations (20)
Florida
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- SFM Clinical Research, LLC - Boca Raton
- K2 Medical Research - Maitland
- Renstar Medical Research - Ocala
- N1 Research LLc - Orlando
- Parkinson's Disease Center of SWFL - Port Charlotte
- University Clinical Research-DeLand, LLC d/b/a Accel Research Sites - Brain & Spine Institute - Port Orange
- USF Parkinson's Disease and Movement Disorders Center - Tampa
Alabama
- The Kirklin Clinic of UAB Hospital - Birmingham
- University of Alabama at Birmingham - Birmingham
Arizona
- Barrow Neurological Institute - Phoenix
- St. Joseph's Hospital and Medical Center - Phoenix
California
- Parkinson's Research Centers of America - Orange county - Aliso Viejo
- Parkinson's Research Centers of America - Palo Alto - Palo Alto
Colorado
- CenExel Rocky Mountain Clinical Research - Englewood
Georgia
- Atlanta Neuroscience Institute - Atlanta
Kansas
- University of Kansas Medical Center - Kansas City
Kentucky
- University of Kentucky, Dept of Neurology Kentucky Neuroscience Institute Research - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2024-09-20 |
| Est. Completion | 2026-03 |
| Phase | Phase 3 |
What NCT06553027 shows while recruiting
NCT06553027 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06553027 names 20 study sites across 10 states, led by Florida, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT06553027 about?
NCT06553027 is a clinical study titled "To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications". This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. ...
What is the current status of trial NCT06553027?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2024-09-20. Estimated completion is 2026-03.
What conditions does trial NCT06553027 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT06553027?
The interventions under investigation include: Placebo (DRUG), CVN424 75 mg (DRUG), CVN424 150 mg (DRUG).
Who is sponsoring clinical trial NCT06553027?
This trial is sponsored by Cerevance, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06553027 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06553027's enrollment target sits among peer trials
330 32nd of 297 higher than 266 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's
RECRUITING · Phase 3
-
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
COMPLETED · Phase 3
-
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
COMPLETED · Phase 3
-
Embryonic Dopamine Cell Implants for Parkinson's Disease
COMPLETED · Phase 3
-
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
COMPLETED · Phase 3
-
Flexible-Dose Trial in Early Parkinson's Disease (PD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI